comparemela.com

Latest Breaking News On - Anna lok - Page 1 : comparemela.com

No racial disparities observed in chronic HBV treatment rates among eligible patients

Although Black individuals with chronic hepatitis B were less likely to meet treatment criteria, researchers reported no significant differences in treatment initiation between racial groups, according to data in JAMA Network Open.“Because Asians and Blacks have higher prevalence of chronic HBV infection and are more likely to develop liver cancer, we examined whether there are racial

German scientist, inventor of world s 1st treatment for hepatitis D, chosen for Blumberg Prize by Hepatitis B Foundation - Brazil Business Today

Bulevirtide Shows Real-World Efficacy Versus HDV

Be Cautious With HBV Drug Withdrawal

Target RWE Shares Weight Loss Data From Ongoing NASH Study

Target RWE Shares Weight Loss Data From Ongoing NASH Study Real-world study shows only 32% of overweight or obese adults with NAFLD in the U.S. achieved 5% or more weight reduction News provided by Share this article DURHAM, N.C., Feb. 2, 2021 /PRNewswire/  Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, shared the latest data from the ongoing TARGET-NASH observational study, published in The nonalcoholic steatohepatitis (NASH) study, Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort, analyzed 2,019 patients enrolled in the TARGET-NASH cohort in the United States over a median follow-up of 39 months. The baseline characteristics included one third of patients classified as obesity class 2/3, 38.6% of patients had diabetes, and approximately 50% had documentation of lifestyle modifications or diet recommendations.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.